Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H15N3O5.2H2O |
| Molecular Weight | 281.2631 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.C\C(=N/O)C1=NC=C(N1)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=AJVKDZILVNPFFC-ZQBMOEMVSA-N
InChI=1S/C9H15N3O5.2H2O/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13;;/h2,6-8,13-17H,3H2,1H3,(H,10,11);2*1H2/b12-4+;;/t6-,7-,8-;;/m1../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C9H15N3O5 |
| Molecular Weight | 245.2325 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
LX 2931 (LX 3305) is an inhibitor of sphingosine 1-phosphate (S1P) lyase. S1P lyase is an enzyme identified as a promising new target on a pathway associated with regulation of the immune system. Lexicon Pharmaceuticals, Inc. was developing LX 2931 for the treatment of rheumatoid arthritis. LX 2931 has disappeared from the pipeline of Lexicon Pharmaceuticals, Inc. In preclinical studies LX 2931 was effective against experimental cerebral malaria, lung inflammation in a F508del CFTR murine cystic fibrosis model and osteoporosis.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). | 2010 Dec 23 |
|
| Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice. | 2019 Aug |
Patents
Sample Use Guides
Phase I clinical trials indicated that LX 2931, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily.
Lexicon Pharmaceuticals, Inc. was planning the Phase 2 clinical trial is designed as a 12-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX2931 and its effects on symptoms associated with rheumatoid arthritis. Three dose levels will be evaluated: a 70 mg dose, a 110 mg dose and a 150 mg dose, each administered once daily.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:05:45 GMT 2023
by
admin
on
Sat Dec 16 14:05:45 GMT 2023
|
| Record UNII |
FKM6EA4G10
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135565640
Created by
admin on Sat Dec 16 14:05:45 GMT 2023 , Edited by admin on Sat Dec 16 14:05:45 GMT 2023
|
PRIMARY | |||
|
1078151-47-9
Created by
admin on Sat Dec 16 14:05:45 GMT 2023 , Edited by admin on Sat Dec 16 14:05:45 GMT 2023
|
PRIMARY | |||
|
FKM6EA4G10
Created by
admin on Sat Dec 16 14:05:45 GMT 2023 , Edited by admin on Sat Dec 16 14:05:45 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |